Log In


Company Name : Boehringer Ingelheim

Thursday, March 1, 2018 11:59PM IST (6:29PM GMT)


Boehringer Ingelheim Starts New Campaign: ‘Why wait in IPF?’

Rare Disease Day draws attention to the importance of early diagnosis and treatment of IPF.; Even though international guidelines recommend to offer antifibrotic treatment to the majority of individuals with IPF, research in Europe shows that around 40% of patients with confirmed IPF do not receive antifibrotic treatment.1; Boehringer Ingelheim provides physicians with insights into progression of IPF as well as the benefits of early diagnosis and intervention.

Ingelheim, Germany

On Rare Disease Day, 28 February, Boehringer Ingelheim emphasises the question: ‘Why wait in IPF?´ while awareness activities are focussing on highlighting the benefits of early diagnosis and considering early treatment of idiopathic pulmonary fibrosis (IPF). IPF is a rare, debilitating and fatal lung disease which affects approximately 3 million people worldwide.2


Diagnosing IPF can be difficult because typically, patients with IPF present with nonspecific symptoms usually attributed to ageing, deconditioning or other comorbidities.2 The median time from first symptoms to diagnosis is around two years.3 Early and accurate diagnosis of IPF is important, as interventions such as antifibrotic therapies, supplemental oxygen treatment, cough management and pulmonary rehabilitation may help patients to better manage their condition.


In IPF a key concern is that many patients who are diagnosed with the disease remain untreated. In 2016, 290 respiratory physicians from five European countries participated in an online survey about IPF treatment in patients under their care. The survey showed that, of patients with a confirmed diagnosis, 40% did not receive treatment.1


IPF is unpredictable and damage is permanent.Without appropriate medical intervention the opportunity to slow disease progression is lost. “Slowing disease progression and preserving lung function by reducing decline should be the primary goal for all physicians when treating individuals with IPF. For this reason, initiation of treatment at diagnosis is vital”, commented Professor Toby Maher, Royal Brompton Hospital, UK.


While a cure for IPF has not been found yet, two approved antifibrotic drugs shown to slow disease progression in IPF are recommended for the majority of patients by international guidelines.4 At the time of diagnosis, IPF patients should feel empowered to take an active approach to managing their disease by learning all they can about it, and discussing with their treating physicians what treatment options and approaches are available.


New resources released for Rare Disease Day can be found at Boehringer-Ingelheim.com.


More information on IPF for physicians can be found at inIPF. Further information for patients can be found at Life with IPF.


~ ENDS ~


Please click on the link below for ‘Notes to Editors’ and ‘References’:




Intended audiences:


This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.





Click here for Media Contact Details

Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Kristin Jakobs
Phone: +49 6132 – 77 144553
Fax: +49 6132 – 77 6601
Email: press@boehringeringelheim.com

More News from Boehringer Ingelheim

20/03/2018 5:45PM

Favorable safety profile of Pradaxa® (dabigatran etexilate) confirmed in large prospective real-world analysis

Complete Phase II results from the prospective GLORIATM-AF registry in dabigatran patients presented as a late-breaker at the EHRA 2018, the annual congress of the European Heart Rhythm Association (EHRA)1 Low ...

19/03/2018 7:15PM

FDA grants Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease ...

07/03/2018 10:59AM

Boehringer Ingelheim and Lilly expand heart failure programme for empagliflozin with new exercise capacity trials

EMPERIAL clinical trials will evaluate the effect of empagliflozin on exercise ability and heart failure symptoms in people with chronic heart failure1,2 EMPERIAL is part of the most comprehensive clinical trial ...

Similar News

22/03/2018 6:15PM

Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal Phase 2 PACE Trial in Blood

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that final data from the pivotal Phase 2 PACE clinical trial of ICLUSIG (ponatinib) in refractory chronic myeloid leukemia (CML) or Philadelphia ...

No Image

22/03/2018 11:42AM

Eye7, AIIMS and Medanta Introduce Contoura Vision Laser Eye Surgery in Delhi-NCR

Contoura Vision Topography-Guided Laser Correction, the most advanced modality of laser vision correction, has now been introduced in India. In fact, despite the fact that Contoura Vision only received US FDA approval ...